CANADA LIFE ASSURANCE Co decreased its holdings in shares of Amdocs Limited (NASDAQ:DOX – Free Report) by 1.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 43,077 shares of the technology company’s stock after selling 822 shares during the quarter. CANADA LIFE ASSURANCE Co’s holdings in Amdocs were worth $3,665,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of DOX. Jones Financial Companies Lllp acquired a new position in Amdocs during the fourth quarter worth $36,000. SBI Securities Co. Ltd. acquired a new position in shares of Amdocs during the 4th quarter valued at about $41,000. Global Retirement Partners LLC raised its stake in shares of Amdocs by 45.6% in the 4th quarter. Global Retirement Partners LLC now owns 559 shares of the technology company’s stock valued at $48,000 after acquiring an additional 175 shares in the last quarter. Private Trust Co. NA lifted its holdings in Amdocs by 121.5% in the 4th quarter. Private Trust Co. NA now owns 671 shares of the technology company’s stock worth $57,000 after purchasing an additional 368 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its position in Amdocs by 199.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 686 shares of the technology company’s stock worth $59,000 after purchasing an additional 457 shares during the period. Institutional investors own 92.02% of the company’s stock.
Amdocs Stock Performance
DOX opened at $86.01 on Friday. The company has a quick ratio of 1.20, a current ratio of 1.16 and a debt-to-equity ratio of 0.22. The stock’s 50 day moving average price is $87.07 and its two-hundred day moving average price is $87.02. The firm has a market capitalization of $9.71 billion, a P/E ratio of 19.96, a price-to-earnings-growth ratio of 1.47 and a beta of 0.59. Amdocs Limited has a 12-month low of $74.41 and a 12-month high of $93.34.
Amdocs Increases Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, April 25th. Investors of record on Monday, March 31st were paid a $0.527 dividend. This represents a $2.11 annualized dividend and a dividend yield of 2.45%. The ex-dividend date of this dividend was Monday, March 31st. This is a boost from Amdocs’s previous quarterly dividend of $0.48. Amdocs’s dividend payout ratio (DPR) is presently 48.72%.
Wall Street Analyst Weigh In
Separately, StockNews.com lowered shares of Amdocs from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 28th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $101.20.
Read Our Latest Research Report on Amdocs
Amdocs Company Profile
Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.
Further Reading
- Five stocks we like better than Amdocs
- Basic Materials Stocks Investing
- Short Sellers Gave Up on These 3 Names Recently
- Conference Calls and Individual Investors
- 3 Boring Stocks Outperforming the Market This Year
- Investing In Automotive Stocks
- If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.